Technical Analysis for PBYI - Puma Biotechnology Inc

Grade Last Price % Change Price Change
grade B 39.03 -3.37% -1.36
PBYI closed down 3.37 percent on Friday, March 22, 2019, on 67 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical PBYI trend table...

Date Alert Name Type % Chg
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 MACD Bearish Signal Line Cross Bearish -3.37%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -3.37%
Mar 21 180 Bullish Setup Bullish Swing Setup -3.37%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.37%
Mar 21 Multiple of Ten Bullish Other -3.37%
Mar 21 Wide Bands Range Expansion -3.37%

Older signals for PBYI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Chemistry Cancer Chemical Compounds Organic Compounds Non Small Cell Lung Cancer Chloroarenes Pyridines Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Protein Kinase Inhibitor Aromatic Amines Her2/Neu Advanced Breast Cancer Nitriles Treatment Of Advanced Breast Cancer Treatment Of Various Forms Of Cancer
Is PBYI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 71.7
52 Week Low 17.6
Average Volume 1,150,540
200-Day Moving Average 37.798
50-Day Moving Average 30.6566
20-Day Moving Average 37.307
10-Day Moving Average 40.219
Average True Range 2.2879
ADX 48.83
+DI 35.377
-DI 11.6243
Chandelier Exit (Long, 3 ATRs ) 37.0363
Chandelier Exit (Short, 3 ATRs ) 32.7237
Upper Bollinger Band 46.6224
Lower Bollinger Band 27.9916
Percent B (%b) 0.59
BandWidth 49.939154
MACD Line 3.031
MACD Signal Line 3.2801
MACD Histogram -0.2491
Fundamentals Value
Market Cap 1.45 Billion
Num Shares 37.2 Million
EPS -8.14
Price-to-Earnings (P/E) Ratio -4.79
Price-to-Sales 0.00
Price-to-Book 37.58
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.52
Resistance 3 (R3) 41.68 41.00 41.11
Resistance 2 (R2) 41.00 40.37 40.93 40.97
Resistance 1 (R1) 40.02 39.98 39.68 39.86 40.83
Pivot Point 39.34 39.34 39.18 39.27 39.34
Support 1 (S1) 38.36 38.71 38.02 38.20 37.23
Support 2 (S2) 37.68 38.32 37.61 37.09
Support 3 (S3) 36.70 37.68 36.96
Support 4 (S4) 36.54